Larimar Therapeutics

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. Currently, the company's leading compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare progressive genetic disorder. Larimar also plans to use its intracellular delivery platform to design additional fusion proteins to target other rare diseases characterized by the lack of intracellular bioactive compounds.